| Document |
Document Title |
|
WO/2004/073658A2 |
Isoflavones are modified by esterification at one or more of the C4', C5, C6, and C7 positions to promote bioavailability, and especially to enhance solubility over the corresponding unesterified isoflavones. Preferred modifications prod...
|
|
WO/2004/074304A1 |
A component represented by the following formula (1) which originates in a natural material (CAMU CAMU; Myrciaria dubia) and has a potent antioxidant activity and a stable whitening effect. An antioxidant agent, a whitening agent, a skin...
|
|
WO/2004/071515A1 |
Process for the preparation of monosaccharide derivatives, providing industrial advantages, including convenience, safety, and economic advantages. The monosaccharide derivatives can be used for the inhibition and prevention of cell adhe...
|
|
WO2004016632B1 |
Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. As the compounds of the subject invention exhibit potent activities against bacteria, including gram positive organisms, they are us...
|
|
WO/2004/067542A1 |
A compound having a structure represented by the following general formula (I): (I) (A is a cyclic group, etc.; R1 and R2 each is alkyl, hydroxymethyl, etc.; and n is 1 or 2); or a pharmacologically acceptable salt or ester of the compou...
|
|
WO/2004/067501A1 |
It is intended to provide a marine pest adhesion inhibitor which originates in Tichocarpus orinitus and has a high safety to fishes and the human body.
|
|
WO/2004/065401A1 |
This invention relates to a new class of polyene polyketides, their pharmaceutically acceptable salts and derivatives, and to methods for obtaining the compounds. One method of obtaining these compounds is by cultivation of novel strains...
|
|
WO/2004/065400A1 |
The present application describes binding epitopes to Helicobacter pylori, namely substances comprising oligosaccharide sequences Hex2(NAc)β4Glc(A)(NAc) and Hex1(A)(NAc)&agr /β3Hex2(NAc) (where Hex1 = Gal, Glc or Man, Hex2 = Gal or Glc...
|
|
WO/2004/064723A2 |
New triterpenoid derivatives with various substituents at the C-17 position of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) were synthesized. Among them, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile (CNDDO), 1-(2-cyano-3...
|
|
WO/2004/062590A2 |
The use of bicyclic carbohydrates for the treatment of parasite infections is described. Different bicyclic carbohydrates have been tested in vitro against a number of protozoa. These compounds also have been screened against viruses, tu...
|
|
WO/2004/063211A1 |
The invention relates to new carbohydrate derivatives of paclitaxel and docetaxel with increased solubility in water as compared to the parent compounds, paclitaxel and docetaxel. These derivatives are produced from naturally occurring p...
|
|
WO/2004/062599A2 |
Compounds that are adjuvants and immunoeffectors are described and claimed. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compositions and methods for us...
|
|
WO/2004/060261A2 |
The invention relates to the novel compounds of formula (I): These compounds are potent factor VIIa inhibitors and are therefore particularly useful for the treatment and/or the prophylaxis of thromboses, apoplexy, cardiac infarction, in...
|
|
WO/2004/058788A1 |
Compounds represented by the general formula (&Verbar ) or pharmacologically acceptable salts thereof: (&Verbar ) wherein Q is oxygen, C1-3 alkylene, -O-Alk-, or -O-Alk-O- (wherein Alk is C1-3 alkylene); R1, R2, and R4 are each independe...
|
|
WO/2004/058787A2 |
This invention relates to hydrolase fluorogenic substrates with improved cell permeability, methods for the preparation thereof, and methods of measuring activities of hydrolases, particularly in cell-based assays. The substrates easily ...
|
|
WO/2004/056842A1 |
The invention relates to a novel method for producing aqueous pastes of alkyl oligoglucoside and/or alkenyl oligoglucoside carboxylic acid salts with a reduced content of organic chlorine compounds. Said method is characterised in that t...
|
|
WO/2004/052903A1 |
The invention relates to substituted fluoroglycoside heterocyclic derivatives of a formula (I), wherein radicals have predefined bonds, to the psychologically tolerated salts thereof and to methods for the preparation thereof. Said compo...
|
|
WO/2004/052901A1 |
The invention relates to methods for producing alkyl polyglucosides containing acid groups, whereby a reaction mixture containing at least one alkyl polyglucoside is reacted with a compound containing at least two COOH groups, in the pre...
|
|
WO/2004/052902A1 |
The invention relates to substituted aromatic fluoroglycoside derivatives of a formula (1), wherein radicals have predefined bonds, to the psychologically tolerated salts thereof, and methods for the preparation thereof. Said compounds c...
|
|
WO/2004/050677A1 |
The present invention relates to prodrugs of pharmaceutical moieties, more specifically antimicrobial agents, methods for their preparation, pharmaceutical formulations containing them and their use in the treatment of microbial infections.
|
|
WO/2004/050098A1 |
A freeze-dried preparation which is a freeze-dried amrubicin preparation, contains L-cystein or a salt thereof, has a water content of 0 to about 4 wt.%, and is stable even in long-term storage; and a process for producing the preparatio...
|
|
WO/2004/048396A1 |
The present invention is directed toward a novel process for the preparation of pyranosides protected at the 1,2,4, and 6 or the 1,3,4 and 6 positions.________________________________________
|
|
WO/2004/045623A1 |
The present invention relates to a phospholipid derivative having a substituted or unsubstituted polyhydroxylated aliphatic carbocycle attached to the sn-1 or sn-2 position of the glycerol backbone, a pharmaceutical composition comprisin...
|
|
WO/2004/043944A1 |
The present invention discloses a method for effectively isolating and purifying a physiological active dauer pheromone compound having the following structural formula I related to aging and stress of C. elegans, and determination of th...
|
|
WO/2004/041828A1 |
An anti−cancer substance has a porphyrin−like molecule conjugated to an anti−cancer drug. In one embodiment, the porphyrin−like molecule is conjugated directly to an anti−cancer drug. In a second embodiment, the porphyrin−lik...
|
|
WO/2004/037272A1 |
It is intended to provide a dengue virus infection inhibitor, as a drug effectively inhibiting the infection with dengue virus, which is characterized by at least containing as the active ingredient a carbohydrate molecule having as an e...
|
|
WO/2004/034960A2 |
The present invention relates to pentose and pentose derivatives that are effective at increasing glucose transport in a non-insulin dependent manner, and to uses thereof for a) treating and/or preventing hyperglycemia; b) treating and/o...
|
|
WO/2004/033473A1 |
The present invention relates to certain glucose-based compounds that have an affinity to P-selectin. Further, the invention relates to the use of these glucose-based compounds for the preparation of pharmaceutical compositions for the t...
|
|
WO/2004/033424A1 |
The present invention relates to propofol derivatives comprising a cyclic or linear amino acid, or a poly- or (oligo)saccharide moiety, a process for preparing said derivatives, a method for anesthetizing a mammal as well as a method for...
|
|
WO/2004/033474A1 |
An acetylated N-acetylglucosamine derivative represented by the following general formula (1) and a hyaluronic acid production promoter containing the same and a skin preparation for external use containing the same. General formula (1):...
|
|
WO/2004/033475A1 |
A tyrosinase activity controlling agent containing, as the active ingredient, a compound having an activity of inhibiting or promoting tyrosinase, an external preparation containing the controlling agent, and a process for producing the ...
|
|
WO/2004/032625A2 |
This invention relates to devices, kits, and methods for eliminating termite colonies. The kits, devices, and methods employ a termiticidal bait matrix containing a) a termiticide selected such that the termiticide causes death to about ...
|
|
WO/2004/031202A2 |
The invention relates to methods for producing condensed palatinose in hydrogenated form, to hydrogenated condensed palatinose produced thereby, to uses of this palatinose, and to foodstuffs and medicaments containing hydrogenated conden...
|
|
WO/2004/028475A2 |
Glycosylceramide analogues are disclosed in which the ceramide moiety and optionally the carbohydrate moiety are modified or replaced. These analogues are useful as immunomodulators, antitumor agents, and as other pharmaceutical agents.
|
|
WO/2004/022565A1 |
A multipurpose linker compound having a structure represented by the following general formula (1): (1) wherein Y has a structure represented by O or NH. In the above formula, X has a multibranched site structure involving 4 hydrocarbon ...
|
|
WO/2004/022583A1 |
A linker compound having a structure represented by the following general formula (1): (1) wherein n is an integer of 1 to 6, and wherein X has a structure being a multi-branched structure moiety comprising three or four hydrocarbon chai...
|
|
WO/2004/020392A1 |
Conversion of a boroxazolidone, a 5-membered cyclic compound derived from an &agr -amino acid, into an &agr -amino acid by an entirely new ring-opening reaction (Umezawa reaction). (I) → (II) (In the formulae, R and R' each means optio...
|
|
WO2003097657A9 |
The present invention relates to novel thioglycosides of D-galactofuranose that have an antimicrobial action, methods for their synthesis, pharmaceutical compositions containing them and methods for the treatment of patients suffering mi...
|
|
WO2002083067A9 |
A prodrug composition containing a cinnamate moiety and a biologically active molecule moiety which can be released by hydrolysis or activated by light is disclosed. The cinnamate moiety can have substituents of various electronically do...
|
|
WO/2004/014931A1 |
It is intended to provide 5-thio-β-D-glucopyranoside compounds represented by the following general formula (i), which show an effect of inhibiting the SGLT2 activity, pharmaceutically acceptable salts thereof or hydrates of the same; a...
|
|
WO/2004/014930A1 |
A process for the production of aryl 5-thio-β-D- aldohexopyranoside derivatives represented by the general formula (&Verbar &Verbar &Verbar ) by reacting, according to the following scheme, a 5-thio-D-aldohexopyranose derivative of the ...
|
|
WO/2004/014373A1 |
The invention provides ophthalmic compositions and methods treating the symptoms of ocular allergies. The principle active ingredient in these compositions and methods is macrolide compound, such as tacrolimus, ascomycin and rapamycin an...
|
|
WO/2004/014929A1 |
New compounds and methods for the preparation of combinatorial libraries of potentially biologically active compounds are based on monosaccharides of formula (I) being a derivative of a furanose or pyranose form of a monosaccharide.
|
|
WO/2004/014928A2 |
The invention relates to a difluorinated gem compound having formula (I) wherein R1 is a group comprising an alkyl chain that is substituted by at least one amine, amide or acid function, R2 is a hydrogen atom H or a free or protected al...
|
|
WO/2004/012774A1 |
Conjugates of porphyrins with chemotherapeutic agents are disclosed, as well as methods of making the conjugates and methods of treating patients with the conjugates. Porphyrin compounds, such as mesoporphyrin IX, can be covalently linke...
|
|
WO/2004/011033A1 |
The present invention relates to a method for the preparation of a compound of formula (I) or pharmaceutically acceptable salts thereof and intermediates thereof, comprising the steps of: a) halogenating a compound of formula (II), resul...
|
|
WO/2004/011476A1 |
The present invention provides novel glycosides and glycoconjugates, glycoamino acids, and methods for the synthesis thereof. In another aspect, the present invention provides novel clustered glycopeptides and methods for the synthesis t...
|
|
WO2002055021A9 |
A glycopolymer composition is provided comprising glycopolymer molecules having a polymer backbone; a first pendent unit comprising a linking group connected to said polymer backbone and a saccharide moiety connected to said linking grou...
|
|
WO/2004/009521A1 |
A remedy or a preventive for diseases with a need for the enhanced production of nerve growth factor (NGF) for the treatment or prevention thereof, an NGF production enhancer and a food, a drink or a feed for enhancing NGF production eac...
|
|
WO/2004/009038A2 |
Cosmetic preparations are disclosed, characterised in comprising an effective amount of glycyrrhetinic acid and derivatives thereof.
|
